Hot Life Science Investor Mandate 3: Private Equity Firm Seeking Broad Range of Therapeutic Opportunities

14 May

A private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium is currently seeking to make investment in the life science space. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spin-offs to $150 million in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

The firm is currently looking for companies in the Therapeutics space. For therapeutics the firm is most interested in companies developing novel biologics however companies developing small molecules or biologic substitutes are also considered for investment. The firm is willing to invest in companies with a product anywhere from pre-clinical to phase III of development although they do require a substantial equity position into selected companies. For companies with an asset that is preclinical the firm tends to not get involved if the round is series C or later. The firm is not interested in later stage companies working with primary care technologies.

The firm considers both private and crossover investments and strongly prefers, if not requires to take a board seat into portfolio companies. The firm also prefers to lead or co-lead any investment syndicates and looks to optimize the asset with additional resources beyond the typical venture investment mandate. The firm also requires that the company’s management be able to clearly articulate the mechanisms and functionality of their technology.

The firm is unlike most traditional early stage investors in that they look to act as a partner, taking the company through to commercialization only selling in an M&A transaction if the price is right or access the public markets, but only if it is advantageous to do so.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: